PMID- 17962208
OWN - NLM
STAT- MEDLINE
DCOM- 20080214
LR  - 20200203
IS  - 1569-8041 (Electronic)
IS  - 0923-7534 (Linking)
VI  - 19
IP  - 1
DP  - 2008 Jan
TI  - ErbB/HER ligands in human breast cancer, and relationships with their receptors, 
      the bio-pathological features and prognosis.
PG  - 73-80
AB  - BACKGROUND: The aim of this study is to provide an expression profile of ErbB/HER 
      ligands in breast cancer. We analysed the relationships with their receptors, the 
      bio-pathological features and prognosis. PATIENTS AND METHODS: Epidermal growth 
      factor (EGF), transforming growth factor-alpha (TGFalpha), amphiregulin (AREG), 
      betacellulin (BTC), heparin-binding EGF-like growth factor (HB-EGF), epiregulin 
      (EREG) and neuregulins1-4 (NRG1-4) were quantified in 363 tumours by real-time 
      reverse transcription-polymerase chain reaction using TaqMan probes. RESULTS: 
      Ligands were detected in 80%-96% of the cases, except NRG3 (42%) and EREG 
      (45.5%). At least one ligand was expressed in 304 cases (cut-off: upper 
      quartile). Almost all combinations of receptor and ligand co-expressions were 
      observed, but TGFalpha is preferentially expressed in tumours co-expressing 
      EGFR/HER3, NRG3 in those co-expressing EGFR/HER4, AREG and EREG in those 
      co-expressing HER2/HER4. EGF and AREG were associated with estradiol receptors, 
      small tumour size, low histoprognostic grading, high HER4 levels. TGFalpha, 
      HB-EGF and NRG2 were negatively related to these parameters. In Cox univariate 
      analyses, EGF was a prognostic factor. CONCLUSION: Our study demonstrates that 
      (i) ErbB/HER ligands, including BTC and EREG, are expressed in most breast 
      cancers; and (ii) TGFalpha, HB-EGF and NRG2 high expressions are related to the 
      biological aggressiveness of the tumours.
FAU - Revillion, F
AU  - Revillion F
AD  - Laboratoire d'Oncologie Moleculaire Humaine, Centre Oscar Lambret, BP 307, 59020 
      Lille Cedex, France. f-revillion@o-lambret.fr
FAU - Lhotellier, V
AU  - Lhotellier V
FAU - Hornez, L
AU  - Hornez L
FAU - Bonneterre, J
AU  - Bonneterre J
FAU - Peyrat, J-P
AU  - Peyrat JP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071024
PL  - England
TA  - Ann Oncol
JT  - Annals of oncology : official journal of the European Society for Medical 
      Oncology
JID - 9007735
RN  - 0 (AREG protein, human)
RN  - 0 (Amphiregulin)
RN  - 0 (BTC protein, human)
RN  - 0 (Betacellulin)
RN  - 0 (EGF Family of Proteins)
RN  - 0 (EREG protein, human)
RN  - 0 (Epiregulin)
RN  - 0 (Glycoproteins)
RN  - 0 (HBEGF protein, human)
RN  - 0 (Heparin-binding EGF-like Growth Factor)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (NRG1 protein, human)
RN  - 0 (NRG2 protein, human)
RN  - 0 (NRG3 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Nerve Growth Factors)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Neuregulin-1)
RN  - 0 (Neuregulins)
RN  - 0 (RNA, Messenger)
RN  - 0 (RNA, Neoplasm)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Transforming Growth Factor alpha)
RN  - 0 (neuregulin-4)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Ann Oncol. 2008 May;19(5):1020-1. PMID: 18356136
MH  - Amphiregulin
MH  - Betacellulin
MH  - Breast Neoplasms/*chemistry/mortality/pathology
MH  - Carcinoma, Ductal, Breast/*chemistry/mortality/pathology
MH  - Carcinoma, Lobular/*chemistry/mortality/pathology
MH  - Disease-Free Survival
MH  - EGF Family of Proteins
MH  - Epidermal Growth Factor/analysis
MH  - Epiregulin
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Gene Expression Profiling
MH  - Glycoproteins/analysis
MH  - Heparin-binding EGF-like Growth Factor
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/analysis
MH  - Intracellular Signaling Peptides and Proteins/analysis
MH  - Neoplasm Invasiveness
MH  - Neoplasm Proteins/*analysis/genetics
MH  - Nerve Growth Factors/analysis
MH  - Nerve Tissue Proteins/analysis
MH  - Neuregulin-1
MH  - Neuregulins/analysis
MH  - Prognosis
MH  - RNA, Messenger/analysis
MH  - RNA, Neoplasm/analysis
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/analysis
MH  - Transforming Growth Factor alpha/analysis
EDAT- 2007/10/27 09:00
MHDA- 2008/02/15 09:00
CRDT- 2007/10/27 09:00
PHST- 2007/10/27 09:00 [pubmed]
PHST- 2008/02/15 09:00 [medline]
PHST- 2007/10/27 09:00 [entrez]
AID - S0923-7534(19)41103-4 [pii]
AID - 10.1093/annonc/mdm431 [doi]
PST - ppublish
SO  - Ann Oncol. 2008 Jan;19(1):73-80. doi: 10.1093/annonc/mdm431. Epub 2007 Oct 24.